

# Earnings Presentation

First Quarter 2024



### Non-GAAP Financial Measures & Cautionary Statements

#### Non-GAAP Financial Measures

This presentation includes certain financial performance measures not defined by generally accepted accounting principles in the United States ("GAAP"), such as Nareit FFO, Net Operating Income ("NOI"), Same-Store Cash NOI, Same-Store Cash NOI Margin, Same-Store Cash NOI Growth and Net Debt to Further Adjusted EBITDA. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in the appendix to this presentation. Our definitions and calculations of these non-GAAP measures may not be the same as similar measures reported by other REITs.

These non-GAAP financial measures should not be considered as alternatives for, or superior to, financial measures calculated in accordance with GAAP.

#### Cautionary Statements

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among others, statements of expectations, beliefs, future plans and strategies, anticipated results from operations and developments and other matters that are not historical facts. Forward-looking statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "assume," "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "forecast," "plan," "potential," "opportunity," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof.

Forward-looking statements are based on management's beliefs as well as on a number of assumptions concerning future events. You should not put undue reliance on these forward-looking statements, which are not a guarantee of performance and are subject to a number of uncertainties and other factors that could cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. We do not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made. We urge you to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance, including those made below and in our filings with the Securities and Exchange Commission, such as in the sections titled "Cautionary Statements – Summary Risk Factors," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023 and our subsequent Quarterly Reports on Form 10-C.

Certain factors that could affect our future results and our ability to achieve our stated goals include, but are not limited to: (a) our ability to achieve the anticipated benefits and synergies from, and effectively integrate, our completed or anticipated acquisitions and investments of properties, including our ownership of the properties included in our equitized loan portfolio; (b) our exposure and the exposure of our tenants, managers and borrowers to complex healthcare and other regulation, including evolving laws and regulations regarding data privacy and cybersecurity and environmental matters, and the challenges and expense associated with complying with such regulation; (c) the potential for significant general and commercial claims, legal actions, regulatory proceedings or enforcement actions that could subject us or our tenants, managers or borrowers to increased operating costs, uninsured liabilities, fines or significant operational limitations, including the loss or suspension of or moratoriums on accreditations, licenses or certificates of need, suspension of or nonpayment for new admissions, denial of reimbursement, suspension, decertification or exclusion from federal, state or foreign healthcare programs or the closure of facilities or communities; (d) the impact of market and general economic conditions on us, our tenants, managers and borrowers and in areas in which our properties are geographically concentrated, including macroeconomic trends and financial market events, such as bank failures and other events affecting financial institutions, market volatility, increases in inflation, changes in or elevated interest and exchange rates, tightening of lending standards and reduced availability of credit or capital, geopolitical conditions, supply chain pressures, rising labor costs and historically low unemployment, events that affect consumer confidence, our occupancy rates and the reliance of our tenants, managers and borrowers on the financial, credit and capital markets and the risk that those markets may be disrupted or become constrained, including as a result of bank failures or concerns or rumors about such events, tightening of lending standards and reduced availability of credit or capital; (f) the secondary and tertiary effects of the COVID-19 pandemic on our business, financial condition and results of operations and the implementation and impact of regulations related to the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") and other stimulus legislation, including the risk that some or all of the CARES Act or other COVID-19 relief payments we or our tenants, managers or borrowers received could be recouped; (g) our ability, and the ability of our tenants, managers and borrowers, to navigate the trends impacting our or their businesses and the industries in which we or they operate, and the financial condition or business prospect of our tenants, managers and borrowers; (h) the risk of bankruptcy, inability to obtain benefits from governmental programs, insolvency or financial deterioration of our tenants, managers, borrowers and other obligors which may, among other things, have an adverse impact on the ability of such parties to make payments or meet their other obligations to us, which could have an adverse impact on our results of operations and financial condition: (i) the risk that the borrowers under our loans or other investments default or that, to the extent we are able to foreclose or otherwise acquire the collateral securing our loans or other investments, we will be required to incur additional expense or indebtedness in connection therewith, that the assets will underperform expectations or that we may not be able to subsequently dispose of all or part of such assets on favorable terms: (i) our current and future amount of outstanding indebtedness, and our ability to access capital and to incur additional debt which is subject to our compliance with covenants in instruments governing our and our subsidiaries' existing indebtedness; (k) the recognition of reserves. allowances, credit losses or impairment charges are inherently uncertain, may increase or decrease in the future and may not represent or reflect the ultimately realize with respect to, the relevant assets, which could have an adverse impact on our results of operations and financial condition; (I) the non-renewal of any leases or management agreement or defaults by tenants or managers thereunder and the risk of our inability to replace those tenants or managers on a timely basis or on favorable terms, if at all; (m) our ability to identify and consummate future investments in or dispositions of healthcare assets and effectively manage our portfolio opportunities and our investments in co-investment vehicles, joint ventures and minority interests, including our ability to dispose of such assets on favorable terms as a result of rights of first offer or rights of first refusal in favor of third parties; (n) risks related to development, redevelopment and construction projects, including costs associated with inflation, rising or elevated interest rates, labor conditions and supply chain pressures, and risks related to increased construction and development in markets in which our properties are located, including adverse effect on our future occupancy rates; (o) our ability to attract and retain talented employees; (p) the limitations and significant requirements imposed upon our business as a result of our status as a REIT and the adverse consequences (including the possible loss of our status as a REIT) that would result if we are not able to comply with such requirements; (q) the ownership limits contained in our certificate of incorporation with respect to our capital stock in order to preserve our qualification as a REIT, which may delay, defer or prevent a change of control of our company; (r) the risk of changes in healthcare law or regulation or in tax laws, guidance and interpretations, particularly as applied to REITs, that could adversely affect us or our tenants, managers or borrowers; (s) increases in our borrowing costs as a result of becoming more leveraged, including in connection with acquisitions or other investment activity and rising or elevated interest rates; (t) our reliance on third-party managers and tenants to operate or exert substantial control over properties they manage for or rent from us, which limits our control and influence over such operations and results; (u) our exposure to various operational risks, liabilities and claims from our operating assets; (v) our dependency on a limited number of tenants and managers for a significant portion of our revenues and operating income; (w) our exposure to particular risks due to our specific asset classes and operating markets, such as adverse changes affecting our specific asset classes and the real estate industry, the competitiveness or financial viability of hospitals on or near the campuses where our outpatient medical buildings are located, our relationships with universities, the level of expense and uncertainty of our research tenants. and the limitation of our uses of some properties we own that are subject to ground lease, air rights or other restrictive agreements; (x) the risk of damage to our reputation; (y) the availability, adequacy and pricing of insurance coverage provided by our policies and policies maintained by our tenants, managers or other counterparties; (z) the risk of exposure to unknown liabilities from our investments in properties or businesses; (aa) the occurrence of cybersecurity threats and incidents that could disrupt our or our tenants', managers' or borrower's operations, result in the loss of confidential or personal information or damage our business relationships and reputation; (bb) the failure to maintain effective internal controls, which could harm our business, results of operations and financial condition; (cc) the impact of merger, acquisition and investment activity in the healthcare industry or otherwise affecting our tenants, managers or borrowers; (dd) disruptions to the management and operations of our business and the uncertainties caused by activist investors; (ee) the risk of catastrophic or extreme weather and other natural events and the physical effects of climate change; (ff) the risk of potential dilution resulting from future sales or issuances of our equity securities; and (qq) the other factors set forth in our periodic filings with the Securities and Exchange Commission.

### Table of Contents

04	First Quarter 2024 Results & Improved 2024 Outlook	21	Driving Strong Execution and Cash Flow Generation Throughout The
06	Delivering Profitable Organic Growth In		Portfolio
	Senior Housing	26	Balance Sheet & Liquidity
16	External Growth Opportunities Focused on Senior Housing	29	Appendix

First Quarter 2024 Results & Improved 2024 Outlook



First Quarter 2024
Financial Performance
and Improved 2024
Outlook<sup>1</sup>

1. Some of the financial measures throughout this presentation are non-GAAP measures. For reconciliations to the most directly comparable GAAP measures, please see the appendix. 2. The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission. 3. A security rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. 4. Includes \$2.5M receipt of cash payment in the quarter amortized on a GAAP basis over approximately 9 years. 5. YoY Triple-Net Same-Store cash NOI growth in 1Q24 would have been 1.3% excluding the impact of a \$4.3M catchup cash collection of rent from a triple-net healthcare tenant in the prior year period

- First Quarter 2024 Normalized FFO per share of \$0.78, an increase of over 5% YoY and led by organic property growth
- Total Company YoY Same-Store cash NOI grew 6.7% in the first quarter of 2024, led by SHOP
  - o SHOP Same-Store cash NOI grew 15.2%, led by U.S. growth of ~18%
    - Strong demand drove seasonally elevated move-ins and acceleration in SHOP Same-Store average occupancy to +240 basis points year-over-year in 1Q24
- 20 bps sequential improvement to 6.7x Net Debt to Further Adjusted EBITDA, driven by ~\$70M of annualized organic growth in SHOP in 1Q24
  - Extended our revolving credit facility with improved pricing through 2028. BBB+ / Baa1 (Stable) ratings recently reaffirmed by S&P and Moody's<sup>3</sup>
- Year to date, closed or is under contract on approximately \$350M of investments focused on senior housing, meeting previously stated full year investment expectations
  - Expect 7-8% going-in yields, priced below replacement cost and low-tomid teens unlevered IRRs

	1Q 2024
Net (Loss) Attributable to Common Stockholders	(\$0.04)
Nareit FFO	\$0.72
Normalized FFO	\$0.78
First Quarter 2024 YoY Same-Store Cash NOI	% Growth
SHOP	15.2%
Outpatient Medical & Research	4.9%4
Triple-Net	(2.0%) <sup>5</sup>
Total Company	6.7%

	As of 2/14/24	As of 5/1/24
Net Income Attributable to Common Stockholders	\$0.00 - \$0.11	\$0.03 - \$0.11
Normalized FFO Per Share Guidance Range	\$3.07 - \$3.18	\$3.10 - \$3.18
Normalized FFO Per Share Guidance Midpoint	\$3.125	\$3.14
Normalized FFO Per Share Growth	~5%	5%+
Same-Store Cash NOI Growth	As of 2/14/24	As of 5/1/24
SHOP	10.0% - 15.0%	12.0% - 16.0%
Outpatient Medical & Research	2.25% - 3.25%	2.5% - 3.25%
Triple-Net	1.0% - 2.0%	1.25% - 2.0%
Total Company	5.0% - 7.5%	6.0% - 8.0%

- Improved Normalized FFO per share guidance for the FY24 to \$3.10 \$3.18 from previous \$3.07 - \$3.18
- Raised Total Company FY24 Same-Store cash NOI guidance midpoint to 7.0% from 6.25%, led by SHOP
- Improved SHOP FY24 Same-Store cash NOI and occupancy FY24 guidance
  - o FY24 Same-Store cash NOI guidance range improved to 12.0% 16.0% from previous 10.0% 15.0%
  - Improved SHOP FY24 average YoY occupancy growth midpoint to ~270bp from ~250bp
- Higher interest rates resulting in increase in interest expense guidance midpoint to \$609M from \$603M
- Increased capital recycling proceeds to \$300M from \$100M

Delivering Profitable Organic Growth in Senior Housing



### Ventas's Senior Housing Operating Portfolio

Top owner of real estate in the large and fragmented U.S. senior housing market

Portfolio positioned in markets with favorable demographics, strong net absorption and affordability

Portfolio positioned in product types with strong growth and margin profiles

Expert operators who leverage the Ventas OI<sup>TM</sup> platform to drive performance

FY24 Guidance as of 2/14/24<sup>1</sup>

FY24 Guidance as of 5/1/24<sup>1</sup>

10% - 15%

SAME-STORE CASH NOI GROWTH

12% - 16%

SAME-STORE CASH NOI GROWTH

\$118M

TOTAL PROJECTED SHOP GAAP NOI GROWTH AT MIDPOINT OF 2024 GUIDANCE RANGE

\$130M

TOTAL PROJECTED SHOP GAAP NOI GROWTH AT MIDPOINT OF 2024 GUIDANCE RANGE

~250bp

SAME-STORE AVERAGE OCCUPANCY **GROWTH PROJECTED IN 2024** 

~270bp

SAME-STORE AVERAGE OCCUPANCY **GROWTH PROJECTED IN 2024** 

~8%

~5%

~2.5%

**SAME-STORE REVENUE GROWTH** 

SAME-STORE REVPOR **GROWTH** 

SAME-STORE OPEXPOR **GROWTH** 


1. The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission




### Senior Housing Growth Opportunity Supported by Supply / Demand Fundamentals

### ACCELERATING DEMOGRAPHIC DEMAND FOR SENIOR HOUSING


- U.S. 80+ population anticipated to grow by 24%+ through 2029
- Leading edge of U.S. Baby Boomers turning 80 in 2026
- In 2024, the over 80 population is expected to grow by ~500,000 per year (up from average of 175K per year in recent years) and that jumps again to ~900,000 per year in 2027



### U.S. Senior Housing Occupied Units Highest On Record (NIC)<sup>1</sup>



### U.S. Senior Housing Multiyear Growth Opportunity Driven By Record Demand & Decelerating New Supply<sup>3,4</sup>






### Lowest Construction Starts in Over a Decade, Supporting Expected Multiyear Net Absorption

### LIMITED NEW SUPPLY

- Low new supply combined with accelerating 80+ population growth expected to drive broad-based multiyear net absorption
- U.S. rolling 4-quarter starts as a % of inventory at lowest level since 2010<sup>1</sup>
- ~99% of SHOP portfolio free from competing construction starts in Q1 2024<sup>2</sup>
- Under construction projects in VTR U.S. SHOP markets total 2.9% of existing inventory and expected to be delivered over multiple years, which would result in ~1% annual deliveries

#### Under Construction Pipeline<sup>1,3</sup>






<sup>1.</sup> Construction data provided by National Investment Center for Seniors Housing & Care ("NIC"); reflects senior housing within NIC's Top 99 markets. 2. Construction data provided by National Investment Center for Seniors Housing & Care ("NIC"); reflects matching majority type senior housing properties started within five miles of Ventas senior housing operating properties within NIC's markets 3. Construction data provided by National Investment Center for Seniors Housing & Care ("NIC"); reflects senior housing properties started within five miles of Ventas senior housing operating properties within NIC's markets. 4. Based on analysis of submarket construction data, qualified 80+ population growth and current senior housing penetration rates with assumed pre-pandemic annual growth in penetration rate

### 

U.S. Senior Housing
Demand Driven
Occupancy
Opportunity

### Senior Housing Occupancy Opportunity

- > U.S. 80+ population expected to grow 24% in the next 5 years vs. 6%
- > 5 years post financial crisis when VTR had peak occupancy of 92%



1. Population estimates from Oxford Economics as of March 2024. 2. Represents U.S. Same Store Occupancy



### Now is the Right Time to Invest in Senior Housing

Attractive investor entry point given current valuations and as Ventas further aligns its portfolio with the growth opportunity.

RIGHT ASSETS

RIGHT OPERATORS<sup>TM</sup>

#### **OUR FOCUSED STRATEGY**

Deliver profitable organic growth in senior housing

#### PRIMARY DRIVERS

Supply / demand environment

Driving performance with Ventas OITM

Value-creating external growth focused on senior housing

#### PRIMARY DRIVERS

Upcoming industry debt maturities

Attractive going-in yield, growth and unlevered IRR opportunities

Drive strong execution and cash flow generation throughout portfolio

#### PRIMARY DRIVERS

Compounding complementary growth

Benefitting from demographic demand

### Our Strategy is Expected to Enhance Total Shareholder Returns by:


- Driving enterprise NOI and normalized FFO per share growth
- Further enhancing portfolio quality and operator diversification
- Increasing SHOP scale
- Enabling strong returns on capital
- Driving stable and growing dividend capacity



## 2024 SHOP Same-Store Cash NOI Key Drivers<sup>1</sup>


- 2024 SHOP Same-Store Cash NOI growth guidance range improved to 12% 16%
- Expected 2024 average occupancy growth improved to ~270bp YoY, led by the U.S. at >300bp
- Expected RevPOR growth in line with prior guidance assumptions and improvement in OpExPOR growth expectations

#### AVERAGE OCCUPANCY GROWTH TREND



<sup>1.</sup> The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission

Strong SHOP Same-Store Performance in 1Q 2024, Led by U.S.<sup>1</sup>




## SHOP SAME-STORE MOVE-INS

- > Represents 113% of prior year
- > U.S. street rates are up +6.9% vs. prior year

SHOP SAME-STORE U.S. IL MOVE-INS

- > U.S. IL move-ins 127% of prior year
- > U.S. IL sequential spot occupancy up +80 bps from 12/31/23 - 3/31/24, outperforming normal seasonal patterns





SHOP SAME-STORE TOUR VOLUMES

- > 9 consecutive months of tours outperforming prior year levels
- > Tour volumes throughout 1Q24 and in April were consistently above prior year levels


1. Totals and segments may not add due to rounding. 2. The SHOP portfolio is comprised of investments in the United States and in Canada. Refer to the non-GAAP reconciliations at the end of this Supplemental for a reconciliation of Same-Store Cash NOI for the SHOP segment to Net Income for the SHOP segment.



### Ventas Operational Insights<sup>TM</sup> Platform

Proprietary data analytics and experiential insights platform drives portfolio actions and optimizes the right combination of markets, assets and operators

- Combines Ventas's in-house operating expertise with data analytics capabilities to drive performance
  - Enhanced by newly hired SVP, Chief Revenue Officer, Senior Housing
- Provides data-driven and experiential insights to influence asset performance and execution, in collaboration with operators' in-market expertise
- Contributes to improving occupancy, revenues, expenses and NOI margins across the portfolio
- Accelerates NOI growth potential
- Significant portfolio management actions since 2020 to optimize the SHOP portfolio through 150+ SHOP operator transitions, 85+ NNN-to-SHOP conversions and 80+ dispositions of non-core assets



STRATEGIC LEVERS Advanced Market Selection Active Real Estate & Asset Management

Comprehensive Operating Alignment

COMPETITIVE ADVANTAGES







### Ventas Operational Insights™

NOI-Generating Capex Investment Results

104

SEASONED PROJECTS COMPLETED PRIOR TO 9/30/23

470bp

1Q24 YOY AVERAGE OCCUPANCY GROWTH

9%+

1Q24 YOY STREET RATE GROWTH

119%

1Q24 MOVE-INS VS. PRIOR YEAR

340bp

1Q24 YOY SPOT OCCUPANCY GROWTH VS. RESPECTIVE NIC MARKET OCCUPANCY ~20%

1Q24 YOY INCREASE IN TOUR CONVERSION RATE

~100 ADDITIONAL COMPLETED PROJECTS IN EARLY STAGES OF REALIZING INCREMENTAL NOI GENERATION

Improved market position creating occupancy opportunity









External Growth Opportunities Focused on Senior Housing



Investment Pipeline of Senior Housing Assets

### ACTIVELY EXECUTING ON SENIOR HOUSING INVESTMENTS

### INVESTMENT STRATEGY ALIGNS WITH VENTAS'S STRENGTHS



Submarkets with supply / demand profile, with strong affordability and meaningful expected net absorption



Investment followed by active asset management (including Ventas OI<sup>TM</sup>)



Primarily expanding with existing operators with proven performance for Ventas



Increases concentration in fast-growing IL / AL / MC combination communities

#### FINANCIALLY ATTRACTIVE TIME TO INVEST



Year 1 FFO per share neutral / accretive



Attractive going-in yields and accretive to NOI growth



Target unlevered IRRs in the low-to-mid teens, pricing below replacement cost



Sellers motivated to transact, creating potential for numerous actionable opportunities



### Senior Housing Investments Aligned to Investment Priorities

### ~\$350M

Closed or under contract focused on senior housing

- Original FY guidance
- 7 8% going-in NOI yield
- Discount to replacement cost
- Low-to-mid teens unlevered IRR expectation

### RECENT INVESTMENT ACTIVITY

	RIGHT MARKETS	RIGHT ASSETS	RIGHT OPERATORS <sup>TM</sup>
Investments Closed or Under Contract <sup>1</sup>	<ul> <li>✓ Average 3-year submarket net absorption of ~1,000 bps</li> <li>✓ 80+ Population growth of ~20% expected through 2029</li> <li>✓ Near zero new supply deliveries expected over next 3 years</li> </ul>	<ul> <li>✓ Attractive investment basis \$241k per unit</li> <li>✓ ~10 year average age</li> <li>✓ Communities averaging 124 units and offering services across IL / AL / MC</li> <li>✓ Going-in NOI margins ~28% with growth potential</li> </ul>	<ul> <li>✓ New, aligned management contracts</li> <li>✓ Proven high performing operators</li> <li>✓ New regional operator relationship with Northeast market expertise</li> </ul>

Pipeline of Additional Senior Housing Investment Opportunities

### 

Senior Housing Investments Closed or Under Contract






### Opportunity to Invest in Senior Housing

Capital markets dislocation is increasing the number of assets with challenged capital structures, making this the right time for Ventas to pursue value-creating external growth opportunities

RIGHT ASSETS

RIGHT OPERATORS<sup>TM</sup>

### Entering the Peak Years for Senior Housing Loan Maturities<sup>1</sup>



Strong pipeline of senior housing investment opportunities with significant growth potential and attractive going-in NOI yields

#### **DRIVEN BY:**

- ~\$19 billion of loans maturing through 2025
- Some owners lack cash flow to cover loans at today's rates and the equity required to properly recapitalize

Disciplined and selective in pursuing high-quality opportunities that provide opportunity for attractive financial returns, in-line with stated investment criteria

Driving Strong Execution and Cash Flow Generation Throughout The Portfolio



### Triple-Net Update



### Brookdale Senior Housing Portfolio

- 121 communities<sup>2</sup> producing ~7% of Ventas Annualized NOI with lease maturity/renewal date of 12/31/25; opportunity for variety of positive outcomes for Ventas
- Ventas's Brookdale Senior Housing Triple-Net portfolio has improved organic operating performance, growing 36% in Q4 2023 YoY (ex HHS Grants allocable to VTR properties)
  - o TTM EBITDARM to rent coverage has improved to ~1.3x TTM at 12/31/23
- The communities are in markets that support potential net absorption of ~1,000bp over next 3 years
- The base term of the Brookdale Lease runs through 12/31/25, and Brookdale has two contractual "all or nothing" 10-year extension options (the first of which is exercisable on or before 11/30/24) at the greater of escalated rent (3%) and fair market rent (capped at 10% more than the prior year's rent)
- Ventas holds warrants exercisable through 12/31/25 for 16.3 million shares of Brookdale common stock at an exercise price of \$3.00 per share


#### Kindred LTAC Portfolio

- 23 properties (Group 2), producing 5% of Ventas Annualized NOI, have a lease maturity date of 4/30/25
  - o Kindred has an "all or nothing" 5-year contractual renewal option for Group 2
    - Ventas and Kindred recently extended the renewal option notice date to 5/31/24
  - Ventas is in active discussions with Kindred and other parties to maximize post 5/1/25 cash NOI from the Group 2 properties
  - o If Kindred does not exercise its renewal option, Ventas and Kindred may still reach a negotiated agreement for some or all of the Group 2 properties
- TTM EBITDARM<sup>3</sup> to rent coverage for Kindred Group 2 properties is approximately 0.9x at 12/31/23
- Kindred has communicated that it projects improving revenue and expense performance trends in 2024
- Kindred parent Scion Health is a corporate guarantor of the master lease
  - Group 2 properties represent approximately 30% of Scion Health's overall EBITDARM



## Demographic Tailwinds Expected to Drive Demand Across Our Portfolio

### 65+ Population Growth Projections (2010 - 2030)<sup>1</sup>



## Growth in the 65+ population expected to drive:

- ✓ INCREASED DEMAND FOR OUTPATIENT MEDICAL CARE
- ✓ INCREASED NEED FOR R&D TO SUPPORT DRUG INNOVATION
- 11,200 people turn 65 each day; 4.1 million will turn 65 in 2024<sup>2</sup>
- 65 year-olds are expected to live 20 more years<sup>2</sup>
- 65+ population accounts for nearly 40% of total U.S. healthcare spend<sup>3</sup> and spends 2.5-5x more than other cohorts
- 65+ individuals visit the doctor at ~3x the rate of the general population<sup>4</sup>
- More than 170 million Americans expected to have at least one chronic condition by 2030<sup>5</sup>
- Chronic conditions drive more than 40% of all outpatient medical visits<sup>4</sup> and significant research
- Pharma R&D expected to grow to \$285B (by 2028)<sup>6</sup>


VENTAS

**Outpatient Medical** Portfolio Delivers Complementary, Compounding Growth

#### **KEY TAKEAWAYS**

> Lillibridge operating platform provides differentiated competitive advantage, generating continued strong results

1. Some of the financial measures throughout this presentation are non-GAAP measures. For reconciliations to the most directly comparable GAAP measures, please see the appendix 2. Peer average includes WELL, PEAK, HR. DOC did not report in 4Q23 and was replaced with AHR 3. Includes \$2.5M receipt of cash payment in the guarter amortized on a GAAP basis over approximately 9 years. 4. As measured by the Kingsley Survey, the most comprehensive performance benchmarking survey in the industry ranking tenant satisfaction across multiple key categories for Outpatient Medical buildings




900K SF of new and renewal deals executed in the quarter, +50% YoY

+300bp ELP occupancy growth since inception; brought 44 assets under Lillibridge management in 2023

4 7% Same-Store Cash NOI growth<sup>3</sup>

#### QUARTERLY SAME-STORE CASH NOI MARGIN<sup>1</sup>

Consistent Strengthening Industry-Leading Margins



#### STRONG TENANT EXPERIENCE

Percentile in tenant satisfaction<sup>4</sup>, improving for the fourth straight year

Straight quarters of 80%+ sustained retention

Straight quarters of 90%+ Same-Store occupancy



### Outpatient Medical and Research Assets Aligned Through Institutional Demand



OM&R Contributes ~\$630M of Annualized NOI<sup>1</sup>

## Balance Sheet & Liquidity

Balance Sheet and Liquidity

1. Available liquidity includes credit facility availability and cash and restricted cash less borrowings under commercial paper program. 2. 2024 consolidated debt maturities exclude recurring principal amortization, 3. Some of the financial measures throughout this presentation are non-GAAP measures. For reconciliations to the most directly comparable GAAP measures, please see the appendix. 4. A security rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. 5. The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission. 6. Capital raised includes both consolidated and unconsolidated activity at 100% share

Liquidity covers remaining 2024 debt maturities by  ${\sim}4x$ 

\$2.75B

Extended and Improved Unsecured Revolving Credit Facility (April 2024)

- Significant committed liquidity
- Extended maturity to April 2028
- Lower borrowing spread

\$3.4B

Of available liquidity as of March 31, 2024<sup>1</sup>

\$1.2B

Maturing debt in 2024<sup>2</sup>

#### COMMITMENT TO FINANCIAL STRENGTH

SHOP NOI growth driving organic deleveraging

~\$70M

Sequential organic growth in SHOP Annualized NOI Leading to

20 bps

Sequential improvement to 6.7x Net Debt / Further Adjusted EBITDA<sup>3</sup> during 1Q24

BBB+(Stable)

Baa1(Stable)

Reaffirmed by S&P<sup>4</sup>

Reaffirmed by Moody's<sup>4</sup>

Provides flexibility in funding external growth and maintaining a strong balance sheet

Capital Recycling Third-Party (Ventas Investment Management)

On Balance Sheet Financing

Internal Cash Flow

\$94M

Issuances of common stock under ATM program year-to-date, match-funding closed investments ~\$300M

Expected disposition proceeds during 2024, an increase of \$200M vs. initial outlook<sup>5</sup>

\$7.8B

Capital raised in 2023 and YTD 2024<sup>6</sup>

- Bank market
- CAD bond market
- Secured debt
- Convertible bond market
- Common equity
- Capital recycling

C\$650M

5.1% Senior Notes (March 2024)

> Addressed 2025 maturities



### Positioned to Create Value



Leader in senior housing in North America with high-quality portfolio serving large and growing aging population



Data-driven insights influencing asset performance, execution and market selection



Attractive valuation and growth profile



Strong operator relationships covering all care and community types



Deeply experienced leadership with a performance culture that wins together



Complementary compounding growth from other asset classes with demographic demand



### 2024 Guidance As of May 1, 2024<sup>1</sup>

Dollars in millions USD, except per share amounts, totals may not sum due to rounding, unaudited

### Net Income and FFO Attributable to Common Stockholders<sup>2</sup>

	FY 2	2024	FY 2024 -	Per Share
	Low	High	Low	High
Net income attributable to common stockholders	\$11	\$45	\$0.03	\$0.11
Depreciation and amortization adjustments	1,214	1,214	2.95	2.95
Nareit FFO attributable to common stockholders	\$1,225	\$1,258	\$2.98	\$3.06
Other adjustments <sup>3</sup>	51	51	0.12	0.12
Normalized FFO attributable to common stockholders	\$1,276	\$1,309	\$3.10	\$3.18
% Year-over-year growth			4%	6%
Weighted average diluted shares (in millions)	411	411		

### Select Guidance Assumptions

- Close ~\$350M of investments focused on senior housing (no further investment activity assumed)
- Dispose of assets for \$300M in net proceeds
- FAD capital expenditures of ~\$250M
- General and administrative expenses expected to approximate \$155M at the guidance midpoint
- Interest expense expected to range from \$604M to \$614M

#### NO<sub>12</sub>

	FY 2	024
	Low	High
NOI	\$2,022	\$2,068
SHOP	827	855
Outpatient Medical & Research	580	585
Triple-Net	594	606
Non-Segment	21	22

<sup>&</sup>lt;sup>1</sup> The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission.

<sup>&</sup>lt;sup>2</sup> Totals may not add due to minor corporate-level adjustments.

<sup>&</sup>lt;sup>3</sup> Other adjustments include the categories of adjustments presented in our FFO and FAD Reconciliation.



2024 Guidance: Year-Over-Year Same-Store Cash NOI by Segment as of May 1, 2024 1,2,3,4

Dollars in millions USD, unless otherwise noted, totals may not sum due to rounding, unaudited

- <sup>1</sup> The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission.
- <sup>2</sup> See Same-Store Cash NOI by Segment reconciliation for a detailed breakout of adjustments for each respective category.
- <sup>3</sup> Total may not sum across due to minor corporate-level adjustments.
- <sup>4</sup> Guidance excludes 2024 potential non-cash GAAP impacts (if any) related to Kindred Group 2 lease renewal or extension.
- <sup>5</sup> Includes real estate depreciation and amortization, corporate depreciation and amortization and amortization of other intangibles.
- <sup>6</sup> Includes interest expense, general, administrative and professional fees (including stock-based compensation), loss (gain) on extinguishment of debt, transaction, transition and restructuring costs, loss (income) from unconsolidated entities, income tax (expense) benefit and other income and expenses.

#### For the Year Ended December 31, 2024

For the Year Ended December 31, 2023

	Tof the Year Ended Beechiber 51, 2024											
	 SHOP		OM&R	1	Triple-Net	No	n-Segment		Total			
<u>High End</u>		-										
Net income attributable to common stockholders								\$	45			
Depreciation and amortization <sup>5</sup>									1,216			
Interest expense, G&A, other income and expenses <sup>6</sup>									807			
NOI	\$ 855	\$	585	\$	606	\$	22		2,068			
Non-cash and non-same-store adjustments	(99)		(86)		(85)		(22)		(292)			
Same-Store Cash NOI	\$ 756	\$	499	\$	521	\$	_	\$	1,776			
Percentage increase	16.0%		3.25%		2.0%		NM		8.0%			
Low End												
Net income attributable to common stockholders								\$	11			

							\$	11
								1,217
								794
\$ 827	\$	580	\$	594	\$	21		2,022
(97)		(84)		(77)		(21)		(279)
\$ 730	\$	496	\$	517	\$	_	\$	1,743
12.0%		2.5%		1.25%		NM		6.0%
\$	\$ <b>730</b>	\$ <b>730</b> \$	(97)     (84)       \$ 730     \$ 496	(97)     (84)       \$ 730     \$ 496	(97)     (84)     (77)       \$ 730     \$ 496     \$ 517	(97)     (84)     (77)       \$ 730     \$ 496     \$ 517	(97)     (84)     (77)     (21)       \$ 730     \$ 496     \$ 517     \$ -	(97)     (84)     (77)     (21)       \$ 730     \$ 496     \$ 517     \$ - \$

SH	IOP	C	DM&R	Triple	e-Net	Non-S	egment		Total
								\$	(41)
									1,418
									548
\$	711	\$	577	\$	605	\$	32		1,925
	(60)		(93)		(95)		(32)		(280)
	(0)		_		1		_		0
\$	652	\$	484	\$	511	\$	_	\$	1,646
	\$ 	(60)	(0)	(60) (93)	(60) (93) (0) –	(60)     (93)     (95)       (0)     -     1	(60) (93) (95) (0) – 1	(60)     (93)     (95)     (32)       (0)     -     1     -	(60)     (93)     (95)     (32)       (0)     -     1     -



Non-GAAP Financial Measures Reconciliation Adjusted EBITDA and Further Adjusted EBITDA

Dollars in thousands USD, totals may not sum due to rounding, unaudited

#### March 31 2024 December 31, 2023

For the Three Months Ended

	Marc	March 31, 2024		nber 31, 2023
Net loss attributable to common stockholders	\$	(14,312)	\$	(90,819)
Adjustments:				
Interest expense		149,933		154,853
Loss on extinguishment of debt, net		252		85
Taxes (including tax amounts in general, administrative and professional fees)		(1,637)		5,743
Depreciation and amortization		300,255		435,276
Non-cash stock-based compensation expense		16,284		5,690
Transaction, transition and restructuring costs		4,677		3,635
Shareholder relations matters		15,714		-
Net income attributable to noncontrolling interests, adjusted for partners' share of consolidated entity EBITDA		(5,353)		(3,491)
Loss from unconsolidated entities, adjusted for Ventas' share of EBITDA from unconsolidated entities		33,746		30,539
Gain on real estate dispositions		(341)		(39,802)
Unrealized foreign currency loss (gain)		6		(320)
Change in fair value of financial instruments		(9,321)		(24,375)
Materially disruptive events, net		1,160		(1,901)
Allowance on loan investments and impairment of unconsolidated entities, net of noncontrolling interest		(68)		(73)
Other normalizing items <sup>1</sup>		2,357		2,750
Adjusted EBITDA	\$	493,352	\$	477,790
Adjustment for current period activity		(658)		1,035
Further Adjusted EBITDA	\$	492,694	\$	478,825
Further Adjusted EBITDA annualized	\$	1,970,776	\$	1,915,300
Total debt	\$	13,555,194	\$	13,490,896
Cash		(632,443)		(508,794)
Restricted cash pertaining to debt		(31,234)		(29,019)
Partners' share of consolidated debt		(298,719)		(297,480)
Ventas' share of unconsolidated debt		602,088		575,329
Net debt	\$	13,194,886	\$	13,230,932

<sup>&</sup>lt;sup>1</sup> Includes adjustments for unusual items, including approximately \$2.4 million primarily related to the settlement by one of our operators of class action litigation in our SHOP segment.



### Net Income to NOI – Trailing 5 Quarters Reconciliation

Dollars in thousands USD, totals may not sum due to rounding, unaudited

	March 31, 2023 June 30,			30, 2023	September 30, 2023		December 31, 2	023	March	31, 2024
Net income (loss) attributable to common stockholders	\$	17,517	\$	103,453	\$	(71,124)	\$ (90	,819)	\$	(14,312)
Adjustments:										
Interest and other income		(1,743)		(1,032)		(2,754)	2)	,885)		(6,780)
Interest expense		128,075		143,265		147,919	15	1,853		149,933
Depreciation and amortization		282,119		304,689		370,377	43.	5,276		300,255
General, administrative and professional fees		44,798		34,399		33,297	3	,382		48,737
(Gain) loss on extinguishment of debt, net		_		(6,801)		612		85		252
Transaction, transition and restructuring costs		1,386		3,069		7,125	:	3,635		4,677
Allowance on loans receivable and investments		(8,064)		(12,065)		(66)		(75)		(68)
Gain on foreclosure of real estate		_		(29,127)		-		-		_
Shareholder relations matters		-		-		-		-		15,714
Other expense (income)		7,762		(17,959)		9,432	(22	,236)		(1,334)
Net income attributable to noncontrolling interests		1,395		1,613		1,565		,103		1,772
Loss (income) from unconsolidated entities		5,623		(31,254)		5,119		,886		8,383
Income tax (benefit) expense		(2,802)		(9,773)		(1,662)		,698		(3,004)
Gain on real estate dispositions		(10,201)		(1,405)		(10,711)	(39	,802)		(341)
NOI	\$	465,865	\$	481,072	\$	489,129	\$ 48	7,101	\$	503,884
SHOP	\$	167,771	\$	177,504	\$	180,702	\$ 18	5,430	\$	203,483
OM&R		136,719		144,195		148,073	14	,945		145,570
Triple-Net		145,943		150,818		155,965	15	,925		151,630
Non-segment		15,432		8,555		4,389	:	3,801		3,201
NOI	\$	465,865	\$	481,072	\$	489,129	\$ 48	7,101	\$	503,884

For the Three Months Ended



Senior Housing
Operating Portfolio
Same-Store Cash
Operating Revenue
& Same-Store Cash
NOI Reconciliations

Dollars in thousands USD, totals may not sum due to rounding, unaudited

Assets that have undergone business model transitions are reflected within the new business segment as of the

		1Q23	2Q23	3Q23	4Q23	1Q24	
Total revenues	\$	704,993	\$	724,614	\$ 754,417	\$ 775,195	\$ 813,304
Adjustments:							
Revenues not included in cash operating revenues <sup>1</sup>		(17,496)		(15,720)	(16,582)	(16,989)	(15,499)
Revenue impact from change in FX		336		(492)	(577)	1,147	_
Cash operating revenue		687,833		708,402	737,258	759,353	797,805
Adjustments:							
Cash operating revenue not included in Same-Store		(46,460)		(65,064)	(83,661)	(95,163)	(106,592)
Cash operating revenue impact from change in FX not in Same-Store	<u> </u>	(3)		5	6	(21)	_
Same-Store Cash Operating Revenue	\$	641,370	\$	643,343	\$ 653,603	\$ 664,169	\$ 691,213
Percentage increase YoY							7.8 %
Percentage increase Seq							4.1 %
		1Q23		2Q23	3Q23	4Q23	1Q24
NOI	\$	167,771	\$	177,504	\$ 180,702	\$ 185,430	\$ 203,483
Adjustments:							
NOI not included in Cash NOI <sup>1</sup>		2,784		2,256	1,760	1,552	1,003
NOI impact from change in FX		128		(197)	(225)	437	_
Cash NOI		170,683		179,563	182,237	187,419	204,486
Adjustments:							
Cash NOI not included in same-store		(11,491)		(14,459)	(18,664)	(20,476)	(21,056)
NOI impact from change in FX not in same-store				11_	11	2	 _
Same-store Cash NOI	\$	159,192	\$	165,105	\$ 163,574	\$ 166,945	\$ 183,430
Percentage increase YoY							15.2 %
Percentage increase Seq							9.9 %
		1Q23		2Q23	3Q23	4Q23	1Q24
USD (\$) to CAD (C\$)	-	1.3519		1.3428	1.3418	1.3607	1.3480

transition date.

<sup>&</sup>lt;sup>1</sup> Includes consolidated properties. Excludes sold assets, assets owned by unconsolidated real estate entities, assets held for sale, loan repayments, development properties not yet operational and land parcels from all periods.



Outpatient Medical and Research Portfolio Same-Store Cash Operating Revenue & Same-Store Cash NOI Reconciliations

Dollars in thousands USD, unless otherwise noted, totals may not sum due to rounding, unaudited

Adjustments:

Same-Store Cash NOI

Percentage increase YoY

Percentage increase Seq

Cash NOI not included in Same-Store

			Trai	ling 5-Quarters		
	 1Q23	2Q23		3Q23	4Q23	1Q24
Total revenues	\$ 203,632	\$ 216,366	\$	226,988	\$ 222,722	\$ 219,508
Adjustments:						
Straight-lining of rental income	(2,345)	(1,958)		(2,350)	(2,989)	(3,290)
Non-cash rental income	(2,573)	(2,177)		(2,484)	(2,144)	(2,136)
Third party management revenues	(628)	(559)		(662)	(666)	(631)
Revenues not included in cash operating revenues <sup>1</sup>	(10,264)	(10,657)		(9,246)	(6,078)	(499)
Cash modification fees	_	_		_	_	2,500
Cash operating revenue	187,822	201,015		212,246	210,845	215,452
Adjustments:						
Cash operating revenue not included in Same-Store	(5,251)	(17,441)		(24,225)	(24,101)	(24,173)
Same-Store Cash Operating Revenue	\$ 182,571	\$ 183,574	\$	188,021	\$ 186,744	\$ 191,279
Percentage increase YoY						4.8 %
Percentage increase Seq						2.4 9
	1Q23	2023		3Q23	4Q23	1024
NOI	\$ 136,719	\$ 144,195	\$	148,073	\$ 147,945	\$ 145,570
Adjustments:						
Straight-lining of rental income	(2,345)	(1,958)		(2,350)	(2,989)	(3,290)
Non-cash rental income	(2,573)	(2,177)		(2,484)	(2,144)	(2,136)
Cash modification fees	(=/5:5/	-		(_, ., .,	(_, ,	2,500
NOI not included in Cash NOI <sup>2</sup>	(6,218)	(6,697)		(5,072)	(3,568)	(344)
Cash NOI	 125,583	133,363		138,167	139,244	142,300

(2,247)

123,336

(9,228)

124,135

(13,163)

125,004

(13,174)

126,070

(12,951)

129,349

4.9 %

2.6 %

Includes consolidated properties. Excludes sold assets, assets owned by unconsolidated real estate entities, assets held for sale, loan repayments, development properties not yet operational and land parcels from all periods. Assets that have undergone business model transitions are reflected within the new business segment as of the transition date.

<sup>&</sup>lt;sup>2</sup> Includes consolidated properties. Excludes sold assets, assets owned by unconsolidated real estate entities, assets held for sale, loan repayments, development properties not yet operational, land parcels and third-party management revenues from all periods. Assets that have undergone business model transitions are reflected within the new business segment as of the transition date.



Non-GAAP Financial Measures Reconciliation First Quarter 2024 Same-Store Cash NOI by Segment

Dollars in thousands USD, unless otherwise noted, totals may not sum due to rounding, unaudited

USD (\$) to CAD (C\$)

1.3480

1.3519

		For the Thre	e Months Ended M	arch 31, 2024			For the Three	e Months Ended Ma	rch 31, 2023	
	SHOP	OM&R	Triple-Net	Non-Segment	Total	SHOP	OM&R	Triple-Net	Non-Segment	Total
NOI	\$ 203,483	\$ 145,570	\$ 151,630	\$ 3,201	\$ 503,884	\$ 167,771	\$ 136,719	\$ 145,943	\$ 15,432	\$ 465,865
Adjustments:										
Straight-lining of rental income	_	(3,290)	679	-	(2,611)	-	(2,345)	1,900	_	(445)
Non-cash rental income	_	(2,136)	(11,507)	-	(13,643)	-	(2,573)	(12,340)	-	(14,913)
Cash modification fees	_	2,500	_	-	2,500	-	_	_	_	_
NOI not included in cash NOI <sup>1</sup>	1,003	(344)	(601)	-	58	2,784	(6,218)	(3,799)	-	(7,233)
Non-segment NOI	-	-	_	(3,201)	(3,201)	-	-	-	(15,432)	(15,432)
NOI impact from change in FX	_	-	_	-	-	128	-	289	_	417
Cash NOI	204,486	142,300	140,201	-	486,987	170,683	125,583	131,993		428,259
Adjustments:										
Cash NOI not included in Same-Store	(21,056)	(12,951)	(11,575)	-	(45,582)	(11,491)	(2,247)	(695)	-	(14,433)
NOI impact from change in FX not in Same-Store	-	-	-	_	-	-	-	-	-	-
	(21,056)	(12,951)	(11,575)	-	(45,582)	(11,491)	(2,247)	(695)		(14,433)
Same-Store Cash NOI	\$ 183,430	\$ 129,349	\$ 128,626	\$ -	\$ 441,405	\$ 159,192	\$ 123,336	\$ 131,298	\$ -	\$ 413,826
Percentage increase (decrease)	15.2%	4.9%	(2.0%)	1	6.7%					
refrentage increase (decrease)	13.2/0		(2.076)	-	0.776					
	1Q24	1Q23								
GBP (£) to USD (\$)	1.2684	1.2150								

<sup>&</sup>lt;sup>1</sup> Includes consolidated properties. Excludes sold assets, assets owned by unconsolidated real estate entities, assets held for sale, loan repayments, development properties not yet operational and land parcels from all periods. Assets that have undergone business model transitions are reflected within the new business segment as of the transition date.



Non-GAAP Financial Measures Reconciliation 2024 Guidance: Year-Over-Year Same-Store Cash NOI by Segment<sup>1,2,3,4</sup>

Dollars in millions USD, unless otherwise noted, totals may not sum due to rounding, unaudited

- <sup>1</sup> The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission.
- $^2\,\mbox{See}$  Same-Store Cash NOI by Segment reconciliation for a detailed breakout of adjustments for each respective category.
- <sup>3</sup> Total may not sum across due to minor corporate-level adjustments.
- <sup>4</sup> Guidance excludes 2024 potential non-cash GAAP impacts (if any) related to Kindred Group 2 lease renewal or extension.
- <sup>5</sup> Includes real estate depreciation and amortization, corporate depreciation and amortization and amortization of other intangibles.
- <sup>6</sup> Includes interest expense, general, administrative and professional fees (including stock-based compensation), loss (gain) on extinguishment of debt, transaction, transition and restructuring costs, loss (income) from unconsolidated entities, income tax (expense) benefit and other income and expenses.

### For the Year Ended December 31, 2024

	Tof the real Ended December 31, 2024													
		SHOP		OM&R	Tri	ple-Net	Non-	Segment		Total				
<u>High End</u>								_						
Net income attributable to common stockholders									\$	45				
Depreciation and amortization <sup>5</sup>										1,216				
Interest expense, G&A, other income and expenses <sup>6</sup>										807				
NOI	\$	855	\$	585	\$	606	\$	22		2,068				
Non-cash and non-same-store adjustments		(99)		(86)		(85)		(22)		(292)				
Same-store Cash NOI	\$	756	\$	499	\$	521	\$	_	\$	1,776				
Percentage increase		16.0%		3.25%		2.0%		NM		8.0%				
<u>Low End</u>														
Net income attributable to common stockholders									\$	11				
Depreciation and amortization <sup>5</sup>										1,217				
Interest expense, G&A, other income and expenses <sup>6</sup>										794				

Interest expense, G&A, other income and expenses <sup>6</sup>					794
NOI	\$ 827	\$ 580	\$ 594	\$ 21	2,022
Non-cash and non-same-store adjustments	(97)	(84)	(77)	(21)	(279)
Same-store Cash NOI	\$ 730	\$ 496	\$ 517	\$ _	\$ 1,743
Percentage increase	12.0%	2.5%	1.25%	NM	6.0%

For the Year Ended December 31, 2023

								-		
	_	SHOP		(	OM&R	Tr	iple-Net	Nor	n-Segment	Total
<u>Prior Year</u>	_									
Net loss attributable to common stockholders										\$ (41)
Depreciation and amortization <sup>5</sup>										1,418
Interest expense, G&A, other income and expenses <sup>6</sup>										548
NOI		\$	711	\$	577	\$	605	\$	32	1,925
Non-cash and non-same-store adjustments			(60)		(93)		(95)		(32)	(280)
NOI impact from change in FX			(0)		_		1		_	0
Same-store Cash NOI	_	\$	652	\$	484	\$	511	\$	_	\$ 1,646

	FY24
GBP (£) to USD (\$)	1.27
USD (\$) to CAD (C\$)	1.35



## FFO and FAD Reconciliation

In thousands, except per share amounts, dollars in USD, totals may not sum due to rounding, unaudited

	For the Three Months E	nded March 31,	Q1 YoY Change
	2024	2023	′24-′23
Net (loss) income attributable to common stockholders	\$ (14,312)	\$ 17,517	n/a
Net (loss) income attributable to common stockholders per share <sup>1</sup>	\$ (0.04)	\$ 0.04	n/a
Adjustments:		-	
Depreciation and amortization on real estate assets	299,614	281,477	
Depreciation on real estate assets related to noncontrolling interests	(3,871)	(4,377)	
Depreciation on real estate assets related to unconsolidated entities	11,805	10,177	
Gain on real estate dispositions	(341)	(10,201)	
Gain (loss) on real estate dispositions related to noncontrolling interests	9	(5)	
Gain on real estate dispositions and other related to unconsolidated entities	-	(180)	
Subtotal: Nareit FFO adjustments	307,216	276,891	
Subtotal: Nareit FFO adjustments per share	\$ 0.75	\$ 0.69	
Nareit FFO attributable to common stockholders	\$ 292,904	\$ 294,408	(1%)
Nareit FFO attributable to common stockholders per share	\$ 0.72	\$ 0.73	(1%)
Adjustments:			
Change in fair value of financial instruments	(9,339)	(583)	
Non-cash income tax benefit	(4,696)	(4,299)	
Loss on extinguishment of debt, net	252	_	
Transaction, transition and restructuring costs	4,677	1,386	
Amortization of other intangibles	96	96	
Non-cash impact of changes to equity plan	7,561	7,222	
Materially disruptive events, net	1,160	4,107	
Allowance on loans receivable and investments	(68)	(8,064)	
Shareholder relations matters	15,714	(0,004)	
Other normalizing items <sup>2</sup>	2,357	_	
Normalizing items related to noncontrolling interests and unconsolidated entities, net	5,955	2,598	
Subtotal: Normalized FFO adjustments	23,669	2,463	
Subtotal: Normalized FFO adjustments per share	\$ 0.06	\$ 0.01	
Normalized FFO attributable to common stockholders	\$ 316,573	\$ 296,871	7%
Normalized FFO attributable to common stockholders per share	\$ 0.78	\$ 0.74	5%
Adjustments:			
Deferred revenue and lease intangibles, net	(13,645)	(14,913)	
Other non-cash amortization, including fair value of debt	7,298	4,154	
Stock-based compensation	8,723	7,837	
Straight-lining of rental income	(2,612)	(445)	
FAD capital expenditures	(45,329)	(40,902)	
Subtotal: Operating FAD adjustments	(45,565)	(44,269)	
Operating FAD attributable to common stockholders	\$ 271,008	\$ 252,602	7%
Transaction, transition and restructuring costs	(4,677)	(2,104)	
Shareholder relations matters	(15,714)	_	
Other items related to noncontrolling interests and unconsolidated entities, net	(972)	(1,087)	21
FAD attributable to common stockholders  Weighted average diluted shares	**************************************	<b>\$ 249,411</b> 403,792	- %

<sup>&</sup>lt;sup>1</sup> Potential common shares are not included in the computation of diluted earnings per share when a loss from continuing operations exists as the effect would be an antidilutive per share amount.

<sup>&</sup>lt;sup>2</sup> Includes adjustments for unusual items, including approximately \$2.4 million primarily related to the settlement by one of our operators of class action litigation in our SHOP segment.



Outpatient
Medical and
Research SameStore Cash NOI
– Trailing 8
Quarters
Reconciliation

Dollars in thousands USD, unless otherwise noted

	20	22	30	22	40	22	10	23	20	23	302	23	40	23	102	24
	2022	2021	3Q22	3Q21	4022	4021	1023	1Q22	2023	2022	3Q23	3Q22	4023	4022	1Q24	1Q23
NOI	\$136,583	\$137,320	\$135,316	\$137,622	\$136,731	\$133,704	\$136,719	\$137,974	\$144,195	\$136,583	\$ 148,073	\$135,316	\$147,945	\$136,731	\$ 145,570	\$136,719
Adjustments:																
Straight-lining of rental income	(2,747)	(1,496)	(1,927)	(1,713)	(2,040)	(2,429)	(2,345)	(2,785)	(1,958)	(2,747)	(2,350)	(1,927)	(2,989)	(2,040)	(4,282)	(2,345)
Non-cash rental income	(3,493)	(4,478)	(2,631)	(5,491)	(2,537)	(5,482)	(2,573)	(5,698)	(2,177)	(3,493)	(2,484)	(2,631)	(2,144)	(2,537)	(1,144)	(2,573)
NOI not included in cash NOI <sup>1</sup>	(576)	(9,583)	(222)	(6,825)	(260)	(1,435)	(471)	(836)	(852)	(1,391)	(377)	(1,544)	(3,434)	(6,133)	(344)	(6,218)
Cash modification/termination fees		12,037	-	-	-	-	-	-	-	-	-	-	-	-	2,500	-
Cash NOI	129,767	133,800	130,536	123,593	131,894	124,358	131,330	128,655	139,208	128,952	142,862	129,214	139,378	126,021	142,300	125,583
Adjustments:																
Cash NOI not included in same-store	(7,065)	(2,922)	(6,588)	(3,203)	(6,551)	(4,220)	(5,900)	(5,776)	(9,859)	(4,361)	(13,576)	(3,760)	(13,826)	(3,359)	(12,951)	(2,247)
Cash termination fees not in same-store	-	(12,037)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	(7,065)	(14,959)	(6,588)	(3,203)	(6,551)	(4,220)	(5,900)	(5,776)	(9,859)	(4,361)	(13,576)	(3,760)	(13,826)	(3,359)	(12,951)	(2,247)
Same-store Cash NOI	\$122,702	\$118,841	\$123,948	\$120,390	\$125,343	\$120,138	\$125,430	\$122,879	\$129,349	\$124,591	\$ 129,286	\$125,454	\$125,552	\$122,662	\$ 129,349	\$123,336
Same-store Cash NOI																
Outpatient Medical	92,510	89,966	93,784	90,684	94,801	91,405	95,695	92,856	99,840	96,169	100,348	97,430	99,758	97,743	102,839	98,208
Research	30,191	28,875	30,164	29,706	30,541	28,732	29,735	30,024	29,509	28,421	28,938	28,023	25,794	24,919	26,510	25,128
Outpatient Medical (OM) and Research	122,702	118,841	123,948	120,390	125,343	120,138	125,430	122,879	129,349	124,591	129,286	125,454	125,552	122,662	129,349	123,336
OM Same-store Cash NOI YoY Growth	2.8%		3.4%		3.7%		3.1%		3.8%		3.0%		2.1%		4.7%	
Outpatient Medical (OM)																
Same-store Cash NOI	92,510	89,966	93,784	90,684	94,801	91,405	95,695	92,856	99,840	96,169	100,348	97,430	99,758	97,743	102,839	98,208
Same-store Cash Operating Revenue	134,763	131,816	136,682	133,314	137,071	132,049	139,900	135,373	144,480	138,640	147,481	140,465	144,887	139,977	149,296	142,423
OM Same-store Cash NOI Margin	68.6%		68.6%		69.2%		68.4%		69.1%		68.0%		68.9%		68.9%	

<sup>&</sup>lt;sup>1</sup> Includes consolidated properties. Excludes sold assets, assets owned by unconsolidated real estate entities, assets held for sale, development properties not yet operational, land parcels and third-party management revenues from all periods.



### 2024 Guidance As of Feb. 14, 2024<sup>1</sup>

Dollars in millions USD, except per share amounts, totals may not sum due to rounding, unaudited

# <sup>1</sup> The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission.

### Net Income and FFO Attributable to Common Stockholders<sup>2</sup>

	FY 2	2024	FY 2024 -	Per Share
	Low	High	Low	High
Net income attributable to common stockholders	\$0	\$47	\$0.00	\$0.11
Depreciation and amortization adjustments	1,209	1,209	2.94	2.94
Nareit FFO attributable to common stockholders	\$1,209	\$1,256	\$2.94	\$3.05
Other adjustments <sup>3</sup>	53	53	0.13	0.13
Normalized FFO attributable to common stockholders	\$1,262	\$1,309	\$3.07	\$3.18
% Year-over-year growth			3%	6%
Weighted average diluted shares (in millions)	411	411		

### NOI<sup>2</sup>

	FY 2	024
	Low	High
NO	\$2,004	\$2.04E
NOI	\$2,004	\$2,065
SHOP	811	847
Outpatient Medical & Research	578	586
Triple-Net	590	606
Non-Segment	25	26

### Select Guidance Assumptions

- The Company's guidance includes the following investment assumptions:
  - ~\$0.35B of senior housing investments (included in non-segment NOI)
  - ~\$0.1B of gross disposition proceeds in 1H24

<sup>&</sup>lt;sup>2</sup> Totals may not add due to minor corporate-level adjustments.

<sup>&</sup>lt;sup>3</sup> Other adjustments include the categories of adjustments presented in our FFO and FAD Reconciliation.



2024 Guidance: Year-Over-Year Same-Store Cash NOI by Segment as of Feb. 14, 2024 <sup>1,2,3</sup>

Dollars in millions USD, unless otherwise noted, totals may not sum due to rounding, unaudited

- <sup>1</sup> The Company's guidance constitutes forward-looking statements within the meaning of the federal securities laws and is based on a number of assumptions that are subject to change and many of which are outside the control of the Company. Actual results may differ materially from the Company's expectations depending on factors discussed herein and in the Company's filings with the Securities and Exchange Commission.
- <sup>2</sup> See Same-Store Cash NOI by Segment reconciliation for a detailed breakout of adjustments for each respective category.
- <sup>3</sup> Total may not sum across due to minor corporate-level
- <sup>4</sup> Includes real estate depreciation and amortization, corporate depreciation and amortization and amortization of other intangibles.
- <sup>5</sup> Includes interest expense, general, administrative and professional fees (including stock-based compensation), loss (gain) on extinguishment of debt, transaction, transition and restructuring costs, loss (income) from unconsolidated entities, income tax (expense) benefit and other income and expenses.

GBP (f) to USD (\$)

USD (\$) to CAD (C\$)

		For the Y	ear Ended Decemb	per 31, 2024
_	CLIOD	OM8.D	Triple Net	Nan Cann

	 SHOP		OM&R	Т	riple-Net	Nor	n-Segment		Total					
<u>High End</u>	 													
Net income attributable to common stockholders								\$	47					
Depreciation and amortization <sup>4</sup>									1,212					
Interest expense, G&A, other income and expenses <sup>5</sup>									806					
NOI	\$ 847	\$	586	\$	606	\$	26		2,065					
Non-cash and non-same-store adjustments	(78)		(87)		(85)		(26)		(276)					
Same-Store Cash NOI	\$ 769	\$	499	\$	521	\$	_	\$	1,789					
Percentage increase	15.0%		3.25%		2.0%		NM		7.5%					
<u>Low End</u>														
Net income attributable to common stockholders								\$	0					
Depreciation and amortization <sup>4</sup>									1 211					

Net income attributable to common stockholders					\$ 0
Depreciation and amortization <sup>4</sup>					1,211
Interest expense, G&A, other income and expenses <sup>5</sup>					793
NOI	\$ 811	\$ 578	\$ 590	\$ 25	2,004
Non-cash and non-same-store adjustments	(76)	(83)	(74)	(25)	(258)
Same-Store Cash NOI	\$ 735	\$ 495	\$ 516	\$ _	\$ 1,746
Percentage increase	10.0%	2.25%	1.0%	NM	5.0%

For the Year Ended December 31, 2023

		Tof the Teal Effect December 31, 2023										
	SI	SHOP		OM&R		Triple-Net		Non-Segment		Total		
<u>Prior Year</u>												
Net loss attributable to common stockholders									\$	(41)		
Depreciation and amortization <sup>4</sup>										1,418		
Interest expense, G&A, other income and expenses <sup>5</sup>										548		
NOI	\$	711	\$	577	\$	605	\$	32		1,925		
Non-cash and non-same-store adjustments		(45)		(93)		(95)		(32)		(266)		
NOI impact from change in FX		3		_		1		_		3		
Same-Store Cash NOI	\$	669	\$	484	\$	511	\$	_	\$	1,663		

FY24

1.27

1.33